Gossamer Bio/GOSS

$1.28

0.79%
-
1D1W1MYTD1YMAX

About Gossamer Bio

Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its product candidates include Seralutinib (GB002), GB5121 and GB7208. GB002 is an inhaled, small molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor in development for the treatment of pulmonary arterial hypertension (PAH). GB5121 is an oral, irreversible, covalent, small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK), in clinical development for the treatment of primary central nervous system lymphoma (PCNSL). GB5121 is selected based on its central nervous system, or CNS, penetration and kinase selectivity. GB7208 is an oral, small molecule, BTK inhibitor in preclinical development for the treatment of multiple sclerosis (MS). GB7208 is focused on undergoing preclinical testing.

Ticker

GOSS

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Faheem Hasnain

Employees

178

Headquarters

San diego, United States

Gossamer Bio Metrics

BasicAdvanced
$293.03M
Market cap
-
P/E ratio
-$1.76
EPS
1.69
Beta
-
Dividend rate

What the Analysts think about Gossamer Bio

Analyst Ratings

Majority rating from 10 analysts.
Buy

Price Targets

Average projection from 8 analysts.
375.78% upside
High $15.00
Low $0.50
$1.28
Current price
$6.09
Average price target

Gossamer Bio Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$0
-
Net income
$-40M
-5.66%
Profit margin
0%
-

Gossamer Bio Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 17.84%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.59
-$0.52
-$0.45
-$0.21
-
Expected
-$0.62
-$0.53
-$0.49
-$0.26
-$0.21
Surprise
-5.31%
-1.81%
-7.98%
-17.84%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Gossamer Bio stock

Buy or sell Gossamer Bio stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing